Sun Pharma Advanced Research Company Limited (SPARC) has announced its unaudited financial results for the quarter ended June 30, 2026. The company reported a standalone net loss of ₹2,098 lakhs, a notable improvement from the net profit of ₹1,76,070 lakhs in the previous quarter ended March 31, 2026, and a loss of ₹5,203 lakhs for the same quarter in the prior year. The board also approved the reclassification of certain promoter group individuals.
SPARC Reports Q1 FY27 Financial Outcomes
Sun Pharma Advanced Research Company Limited (SPARC) has officially released its unaudited financial results for the first quarter of the fiscal year 2027, concluding on June 30, 2026. The announcement, dated August 10, 2026, details the company’s financial performance and key corporate decisions made during the period.
Standalone Financial Performance
For the quarter ended June 30, 2026, SPARC reported a standalone net loss of ₹2,098 lakhs. This contrasts with a significant profit of ₹1,76,070 lakhs in the preceding quarter ended March 31, 2026. The results for the corresponding quarter of the previous year, ended June 30, 2025, showed a standalone net loss of ₹5,203 lakhs.
Consolidated Financial Performance
On a consolidated basis, SPARC recorded a net loss of ₹2,078 lakhs for the quarter ended June 30, 2026. This also represents an improvement from the net profit of ₹1,76,134 lakhs in the quarter ended March 31, 2026. The consolidated net loss for the quarter ended June 30, 2025, stood at ₹5,187 lakhs.
Key Corporate Decisions
The Board of Directors also approved the unaudited financial results for the quarter. Additionally, the board approved requests for the reclassification of certain promoter group individuals to the ‘Public’ category, subject to necessary regulatory approvals. The board meeting commenced at 11:00 AM IST and concluded at 01:10 PM IST.
Other Comprehensive Income
In terms of Other Comprehensive Income (OCI), the standalone results show items that will not be reclassified to profit or loss, including a net actuarial gain/loss on employee defined benefit plan, amounting to ₹107 lakhs for the quarter ended June 30, 2026. The consolidated OCI figures include an item of ₹107 lakhs in this category as well.
Earnings Per Share
Basic and diluted earnings/(loss) per equity share for the standalone results for the quarter ended June 30, 2026, were (₹0.65). For the consolidated results, the figure was (₹0.64).
Source: BSE
